<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477490</url>
  </required_header>
  <id_info>
    <org_study_id>FE992026 CS29</org_study_id>
    <nct_id>NCT00477490</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study With a Double Blind Extension Investigating the Efficacy and Safety of a Fast- Dissolving (&quot;Melt&quot;) Formulation of Desmopressin for the Treatment of Nocturia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of several doses of the
      melt formulation of desmopressin in a broad population of adult patients with nocturia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Change From Baseline in Mean Number of Nocturnal Voids at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>The number of nocturnal voids was the average over 3 consecutive 24-hours periods prior to Day 1 and prior to the week 4 visit as recorded in participant diaries.
This was the first co-primary outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Percentage of Participants With Greater Than 33 Percent Reduction From Baseline in Mean Number of Nocturnal Voids at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>Percentage of participants in each treatment arm that had a greater than 33% reduction from baseline to the end of Part I (week 4) in mean number of nocturnal voids. Nocturnal void data were recorded in participant diaries.
This was the second co-primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part II: Change From Baseline in Mean Number of Nocturnal Voids to Days 29, 57, 113 and 169</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Days 29, 57, 113 and 169</time_frame>
    <description>Part II outcomes tested the durability of the effect observed in Part I. The number of nocturnal voids was the average over 3 consecutive 24-hours periods prior to Part I baseline and prior to the Part II visit as recorded in participant diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants With Greater Than 33 Percent Reduction From Baseline in Mean Number of Nocturnal Voids to Days 29, 57, 113 and 169</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Days 29, 57, 113 and 169</time_frame>
    <description>Part II outcomes tested the durability of the effect observed in Part I. Percentage of participants in each treatment arm that had a greater than 33% reduction from baseline to Days 29, 57, 113 and 169 in mean number of nocturnal voids. Nocturnal void data were recorded in participant diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Change From Baseline in Total Reported Sleep Time at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>Total sleep time was recorded by participants in study diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Change From Baseline in Initial Period of Undisturbed Sleep at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>Initial period of undisturbed sleep was the time elapsed from first falling asleep until either first void or morning arising. Data were captured in patient diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Change From Baseline in Quality of Life Assessed by The International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>The ICIQ-N is a self-administered questionnaire designed to assess the frequency and bother of daytime and nighttime urination. Subjects were asked to rate the degree of bother of daytime urination and nighttime urination on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate lower quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Change From Baseline in the Two Domain Scores of the Nocturia Quality of Life (NQoL) Questionnaire at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>The NQoL questionnaire is a self-administered questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The twelve core questions are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. Domain summary scores were calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Change From Baseline in Quality of Sleep as Assessed by the Global Score of the Pittsburgh Sleep Quality Index (PSQI) at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>The PSQI is a self-administered 19-item questionnaire designed to assess sleep quality and disturbances. The global score ranges from 0 (better sleep quality) to 21 (worse sleep quality). Higher numbers indicate lower quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Change From Baseline in the Mental Health Summary and the Physical Health Summary of the Short Form-12 Version 2 (SF-12v2) at Week 4</measure>
    <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
    <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions. Data were analyzed using norm-based scoring and summarized along 2 dimensions: Physical Health Summary and Mental Health Summary. Each summary has a range from 0 (poor health) to 100 (highest level of health). Higher numbers indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Participants With Treatment-Emergent Adverse Events (AEs) During Study Part I</measure>
    <time_frame>Day 1 up to Week 4 (end of Part I)</time_frame>
    <description>A treatment-emergent adverse event (AE) was any AE occurring during the treatment period or a pretreatment AE that worsened in intensity during the treatment period. The treatment period was the period during which a subject received investigational medicinal product. If a subject discontinued the investigational medicinal product, the date of last dose was the last day of the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Participants With Treatment-Emergent Adverse Events (AEs) During Study Part II</measure>
    <time_frame>Week 5 up to Day 169</time_frame>
    <description>A treatment-emergent adverse event (AE) was any AE occurring during the treatment period or a pretreatment AE that worsened in intensity during the treatment period. The treatment period was the period during which a subject received investigational medicinal product. If a subject discontinued the investigational medicinal product, the date of last dose was the last day of the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">799</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desmopressin melt 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desmopressin melt 25 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desmopressin melt 50 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desmopressin melt 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desmopressin acetate</intervention_name>
    <description>Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg</description>
    <arm_group_label>desmopressin melt 10 μg</arm_group_label>
    <arm_group_label>desmopressin melt 25 μg</arm_group_label>
    <arm_group_label>desmopressin melt 50 μg</arm_group_label>
    <arm_group_label>desmopressin melt 100 μg</arm_group_label>
    <other_name>Minirin® Melt</other_name>
    <other_name>Nocturin®</other_name>
    <other_name>FE992026</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Written informed consent prior to the performance of any study-related activity.

          2. Patients 18 years and older with an average of ≥ 2 nocturnal voids per night as
             determined by a 3 day frequency-volume chart during the screening period.

        Exclusion Criteria:

        Males:

          1. Clinical suspicion of bladder outlet obstruction and/or urine flow &lt; 5 ml/s. If
             medical history and/or physical examination suggest bladder outlet obstruction,
             uroflowmetry should be performed to confirm the diagnosis

          2. Surgical treatment for bladder outlet obstruction/benign prostatic hyperplasia
             performed within the past 6 months

             Females:

          3. Pregnancy. Females of reproductive age must have documentation of a reliable method of
             contraception.

          4. Use of pessary for pelvic prolapse.

          5. Unexplained pelvic mass.

             Males and Females:

          6. Clinical suspicion of urinary retention and/or post void residual volume &gt; 150 ml. If
             medical history and/or physical examination suggest urinary retention, bladder
             ultrasound or catheterization should be performed to confirm the diagnosis.

          7. Current or past urologic malignancy (e.g., bladder cancer, prostate cancer).

          8. Clinical evidence of current genitourinary tract pathology that could interfere with
             voiding.

          9. History of neurogenic detrusor activity (previously known as detrusor hyperreflexia).

         10. Suspicion or evidence of cardiac failure.

         11. Uncontrolled hypertension.

         12. Uncontrolled diabetes mellitus.

         13. Renal insufficiency. Serum creatinine must be within normal limits and estimated
             glomerular filtration rate (eGFR) &gt;=60 mL/min.

         14. Active hepatic and/or biliary disease. Aspartate transaminase (AST) or alanine
             transaminase (ALT) should not be &gt;2 times the upper limit of normal. Total bilirubin
             should not be &gt; 1.5 mg/dL.

         15. Hyponatremia. Serum sodium level must be within normal limits

         16. Syndrome of Inappropriate antidiuretic hormone secretion (SIADH).

         17. Diabetes insipidus (urine output &gt; 40 ml/kg over 24 hours) as determined by the 3-day
             voiding diary.

         18. Psychogenic or habitual polydipsia

         19. Obstructive sleep apnea

             Other

         20. Known alcohol or substance abuse

         21. Work or lifestyle potentially interfering with regular nighttime sleep (e.g., shift
             workers)

         22. Previous desmopressin treatment for nocturia.

         23. Any other medical condition, laboratory abnormality, psychiatric condition, mental
             incapacity or language barrier that, in the judgment of the investigator, could impair
             patient participation in the trial.

         24. Use of loop diuretics (furosemide, torsemide, ethacrynic acid). Other classes of
             diuretics (thiazides, triamterene, chlorthalidone, amiloride, indapamide) were
             permitted, either as monotherapy or combination therapy. Subjects using a diuretic
             were to be encouraged to take it in the morning, if medically feasible.

         25. Use of any other investigational drug within 30 days of screening.

        Concomitant Medications

        The following medications are permitted provided that the subject has been on a stable dose
        for the 3 months prior to the screening date (i.e. treatment has not been initiated or
        discontinued and there has been no change in dose):

          -  Alpha-blockers: Cardura (doxazosin); Flomax (tamsulosin); Hytrin (terazosin);
             Uroxatral (alfuzosin)

          -  5 alpha-reductase inhibitors: Avodart (dutasteride); Proscar (finasteride)

          -  Antispasmodic, anticholinergic, antimuscarinic therapy for overactive bladder: Detrol,
             Detrol LA (tolterodine); Ditropan, Ditropan XL (oxybutynin); Enablex (darifenacin);
             Levsin(hyoscyamine); Oxytrol transdermal (oxybutynin); Sanctura (trospium); Vesicare
             (solifenacin)

          -  Sedative/hypnotic medications for sleep disorders

          -  Selective serotonin and mixed norepinephrine/serotonin reuptake inhibitors: Celexa
             (citalopram); Cymbalta (duloxetine); Effexor (venlafaxine); Lexapro (escitalopram);
             Paxil(paroxetine); Prozac (fluoxetine); Zoloft (sertraline)

          -  Chronic use of nonsteroidal anti-inflammatory agents

          -  Diabinese (chlorpropamide)

          -  Carbamazepine (carbatrol/tegretol)

          -  Amiodarone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Primary Care Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Urology Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Professional Research</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Uro-Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Research</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Center, LLC</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medsearch Professional Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Group, Inc.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Urology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - PC</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Kansas City</name>
      <address>
        <city>Overland park</city>
        <state>Kansas</state>
        <zip>66202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierremont Women's Clinic</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureCare Studies, Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinic of Lincoln, P.C</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdvanceMed Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Urology</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Group of New Mexico, PC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Urology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - Adult &amp; Pediatric Urology</name>
      <address>
        <city>Carmel</city>
        <state>New York</state>
        <zip>10512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ferring Pharmaceutical Inc</name>
      <address>
        <city>Suffern</city>
        <state>New York</state>
        <zip>10901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Urology Research</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Medical Research</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Akron</name>
      <address>
        <city>Mogadore</city>
        <state>Ohio</state>
        <zip>44260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of SE PA</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Clinical Research, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Concepts</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Group</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Medical Research</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Central Women's Care</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Medical Center and Diagnostic</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia PC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - Medical Professional</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Interior Medical Center</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y-2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - Professional Corporation</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male/Female Health and Reserach</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brantford Urology Research</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R 4N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guelph Urology Associates</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 4Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fe/Male Health Centres</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Juul KV, Klein BM, Nørgaard JP. Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn. 2013 Apr;32(4):363-70. doi: 10.1002/nau.22306. Epub 2012 Sep 12. Review.</citation>
    <PMID>22972524</PMID>
  </reference>
  <results_reference>
    <citation>Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012 Apr;31(4):441-7. doi: 10.1002/nau.22243. Epub 2012 Mar 22.</citation>
    <PMID>22447415</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2007</study_first_posted>
  <results_first_submitted>June 16, 2015</results_first_submitted>
  <results_first_submitted_qc>September 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2015</results_first_posted>
  <disposition_first_submitted>June 2, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eighty-eight (88) sites were initiated in the United States and Canada, and 81 of these sites screened subjects; 78 sites enrolled and randomized subjects.
A total of 1412 subjects were screened for Part I of the study; 613 subjects were screening failures.</recruitment_details>
      <pre_assignment_details>Potential subjects were given a sleep/voiding diary and urine collection device to record the time and volume of each void for 3 consecutive 24-hour periods.
Randomization was stratified by age (&lt;65, ≥65 years) and by the absence/presence of nocturnal polyuria, defined as a ratio of nighttime urine volume/24-hour urine volume ≥33%.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="P2">
          <title>Desmopressin Melt 10 μg</title>
          <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="P3">
          <title>Desmopressin Melt 25 μg</title>
          <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="P4">
          <title>Desmopressin Melt 50 μg</title>
          <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="P5">
          <title>Desmopressin Melt 100 μg</title>
          <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="P6">
          <title>Placebo to 10 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 10 μg once daily about an hour before bedtime.</description>
        </group>
        <group group_id="P7">
          <title>Placebo to 25 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 25 μg once daily about an hour before bedtime.</description>
        </group>
        <group group_id="P8">
          <title>Placebo to 50 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 50 μg once daily about an hour before bedtime.</description>
        </group>
        <group group_id="P9">
          <title>Placebo to 100 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 100 μg once daily about an hour before bedtime.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part I: 4 Week Efficacy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="158"/>
                <participants group_id="P5" count="160"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT Population</title>
              <participants_list>
                <participants group_id="P1" count="156">Received at least one dose of study drug and provided at least one primary efficacy measure.</participants>
                <participants group_id="P2" count="155">Received at least one dose of study drug and provided at least one primary efficacy measure.</participants>
                <participants group_id="P3" count="152">Received at least one dose of study drug and provided at least one primary efficacy measure.</participants>
                <participants group_id="P4" count="148">Received at least one dose of study drug and provided at least one primary efficacy measure.</participants>
                <participants group_id="P5" count="146">Received at least one dose of study drug and provided at least one primary efficacy measure.</participants>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="148"/>
                <participants group_id="P4" count="138"/>
                <participants group_id="P5" count="135"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serum Sodium &lt;= 125mmol/L</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Reported</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part II: Extension Week 5 up to Day 169</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="135"/>
                <participants group_id="P4" count="132"/>
                <participants group_id="P5" count="127"/>
                <participants group_id="P6" count="31"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="34"/>
                <participants group_id="P9" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="120"/>
                <participants group_id="P5" count="107"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="29"/>
                <participants group_id="P9" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decreased sodium</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographic data offered from the Intent-to-Treat population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants took a placebo ‘melt’ for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
        </group>
        <group group_id="B2">
          <title>Desmopressin Melt 10 μg</title>
          <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="B3">
          <title>Desmopressin Melt 25 μg</title>
          <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="B4">
          <title>Desmopressin Melt 50 μg</title>
          <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="B5">
          <title>Desmopressin Melt 100 μg</title>
          <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="152"/>
            <count group_id="B4" value="148"/>
            <count group_id="B5" value="146"/>
            <count group_id="B6" value="757"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="13.39"/>
                    <measurement group_id="B2" value="61.7" spread="14.41"/>
                    <measurement group_id="B3" value="62.4" spread="13.22"/>
                    <measurement group_id="B4" value="61.6" spread="11.80"/>
                    <measurement group_id="B5" value="62.1" spread="12.34"/>
                    <measurement group_id="B6" value="62.0" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="111"/>
                    <measurement group_id="B6" value="609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnic Origin</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="140"/>
                    <measurement group_id="B6" value="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part I: Change From Baseline in Mean Number of Nocturnal Voids at Week 4</title>
        <description>The number of nocturnal voids was the average over 3 consecutive 24-hours periods prior to Day 1 and prior to the week 4 visit as recorded in participant diaries.
This was the first co-primary outcome.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>Intent to treat (ITT) population --All randomized participants who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., nocturnal voids) during Part I were included in the ITT analysis dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in Mean Number of Nocturnal Voids at Week 4</title>
          <description>The number of nocturnal voids was the average over 3 consecutive 24-hours periods prior to Day 1 and prior to the week 4 visit as recorded in participant diaries.
This was the first co-primary outcome.</description>
          <population>Intent to treat (ITT) population --All randomized participants who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., nocturnal voids) during Part I were included in the ITT analysis dataset</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="1.054"/>
                    <measurement group_id="O2" value="-0.83" spread="1.069"/>
                    <measurement group_id="O3" value="-1.00" spread="1.125"/>
                    <measurement group_id="O4" value="-1.18" spread="1.187"/>
                    <measurement group_id="O5" value="-1.43" spread="1.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9303</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.221</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3104</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.120</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.353</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The trial was to be declared positive only if in the 100 μg group, a statistically significant positive effect as compared to placebo on both co-primaries was demonstrated. And only then, the next higher dose group (i.e., 50 μg) could be claimed superior to placebo, if it showed a statistically significant improvement over placebo on both co-primaries.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0207</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.277</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.511</ci_lower_limit>
            <ci_upper_limit>-0.042</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The trial was to be declared positive only if in the 100 μg group, a statistically significant positive effect as compared to placebo on both co-primaries was demonstrated. And only then, the next higher dose group (i.e., 50 μg) could be claimed superior to placebo, if it showed a statistically significant improvement over placebo on both co-primaries.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.613</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.848</ci_lower_limit>
            <ci_upper_limit>-0.378</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part I: Percentage of Participants With Greater Than 33 Percent Reduction From Baseline in Mean Number of Nocturnal Voids at Week 4</title>
        <description>Percentage of participants in each treatment arm that had a greater than 33% reduction from baseline to the end of Part I (week 4) in mean number of nocturnal voids. Nocturnal void data were recorded in participant diaries.
This was the second co-primary outcome.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>Intent to treat (ITT) population --All randomized participants who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., nocturnal voids) during Part I were included in the ITT analysis dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Participants With Greater Than 33 Percent Reduction From Baseline in Mean Number of Nocturnal Voids at Week 4</title>
          <description>Percentage of participants in each treatment arm that had a greater than 33% reduction from baseline to the end of Part I (week 4) in mean number of nocturnal voids. Nocturnal void data were recorded in participant diaries.
This was the second co-primary outcome.</description>
          <population>Intent to treat (ITT) population --All randomized participants who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., nocturnal voids) during Part I were included in the ITT analysis dataset</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9420</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.647</ci_lower_limit>
            <ci_upper_limit>1.598</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5527</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.729</ci_lower_limit>
            <ci_upper_limit>1.807</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The trial was to be declared positive only if in the 100 μg group, a statistically significant positive effect as compared to placebo on both co-primaries was demonstrated. And only then, the next higher dose group (i.e., 50 μg) could be claimed superior to placebo, if it showed a statistically significant improvement over placebo on both co-primaries.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2662</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.296</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.821</ci_lower_limit>
            <ci_upper_limit>2.050</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The trial was to be declared positive only if in the 100 μg group, a statistically significant positive effect as compared to placebo on both co-primaries was demonstrated. And only then, the next higher dose group (i.e., 50 μg) could be claimed superior to placebo, if it showed a statistically significant improvement over placebo on both co-primaries.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori statistically significant difference versus placebo is p≤0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment difference and 95% CI were adjusted for age, absence/presence of nocturnal polyuria, and baseline number of nocturnal voids.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.893</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.795</ci_lower_limit>
            <ci_upper_limit>4.715</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Change From Baseline in Mean Number of Nocturnal Voids to Days 29, 57, 113 and 169</title>
        <description>Part II outcomes tested the durability of the effect observed in Part I. The number of nocturnal voids was the average over 3 consecutive 24-hours periods prior to Part I baseline and prior to the Part II visit as recorded in participant diaries.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Days 29, 57, 113 and 169</time_frame>
        <population>Observed Cases (OC) Analysis Set which consisted of participants who had information on mean number of nocturnal voids for both the screening visit and the final visit in Part I (Day 28) and did not have any major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Placebo to 10 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 10 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O6">
            <title>Placebo to 25 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 25 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O7">
            <title>Placebo to 50 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 50 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O8">
            <title>Placebo to 100 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 100 μg once daily about an hour before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Change From Baseline in Mean Number of Nocturnal Voids to Days 29, 57, 113 and 169</title>
          <description>Part II outcomes tested the durability of the effect observed in Part I. The number of nocturnal voids was the average over 3 consecutive 24-hours periods prior to Part I baseline and prior to the Part II visit as recorded in participant diaries.</description>
          <population>Observed Cases (OC) Analysis Set which consisted of participants who had information on mean number of nocturnal voids for both the screening visit and the final visit in Part I (Day 28) and did not have any major protocol deviations.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (n=104,100,93,104,22,28,27,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="1.161"/>
                    <measurement group_id="O2" value="-1.31" spread="1.163"/>
                    <measurement group_id="O3" value="-1.43" spread="1.273"/>
                    <measurement group_id="O4" value="-1.47" spread="1.080"/>
                    <measurement group_id="O5" value="-1.20" spread="0.912"/>
                    <measurement group_id="O6" value="-1.19" spread="1.215"/>
                    <measurement group_id="O7" value="-1.00" spread="1.140"/>
                    <measurement group_id="O8" value="-1.58" spread="1.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=86,85,78,81,17,24,21,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="1.147"/>
                    <measurement group_id="O2" value="-1.42" spread="1.231"/>
                    <measurement group_id="O3" value="-1.50" spread="1.156"/>
                    <measurement group_id="O4" value="-1.74" spread="1.036"/>
                    <measurement group_id="O5" value="-1.08" spread="0.618"/>
                    <measurement group_id="O6" value="-1.53" spread="1.183"/>
                    <measurement group_id="O7" value="-1.03" spread="1.264"/>
                    <measurement group_id="O8" value="-1.35" spread="1.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=53,56,49,47,11,15,13,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.195"/>
                    <measurement group_id="O2" value="-1.56" spread="1.158"/>
                    <measurement group_id="O3" value="-1.65" spread="1,279"/>
                    <measurement group_id="O4" value="-1.95" spread="1.088"/>
                    <measurement group_id="O5" value="-0.76" spread="0.870"/>
                    <measurement group_id="O6" value="-1.67" spread="1.039"/>
                    <measurement group_id="O7" value="-1.21" spread="1.085"/>
                    <measurement group_id="O8" value="-1.76" spread="1.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=17,15,17,15,3,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.537"/>
                    <measurement group_id="O2" value="-1.71" spread="1.214"/>
                    <measurement group_id="O3" value="-1.65" spread="0.916"/>
                    <measurement group_id="O4" value="-1.76" spread="0.801"/>
                    <measurement group_id="O5" value="-1.78" spread="0.192"/>
                    <measurement group_id="O6" value="-2.00" spread="2.000"/>
                    <measurement group_id="O7" value="-2.33" spread="0.272"/>
                    <measurement group_id="O8" value="-2.50" spread="1.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Percentage of Participants With Greater Than 33 Percent Reduction From Baseline in Mean Number of Nocturnal Voids to Days 29, 57, 113 and 169</title>
        <description>Part II outcomes tested the durability of the effect observed in Part I. Percentage of participants in each treatment arm that had a greater than 33% reduction from baseline to Days 29, 57, 113 and 169 in mean number of nocturnal voids. Nocturnal void data were recorded in participant diaries.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Days 29, 57, 113 and 169</time_frame>
        <population>Observed Cases (OC) Analysis Set which consisted of participants who had information on mean number of nocturnal voids for both the screening visit and the final visit in Part I (Day 28) and did not have any major protocol deviations. Participants had data representing the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Placebo to 10 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 10 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O6">
            <title>Placebo to 25 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 25 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O7">
            <title>Placebo to 50 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 50 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O8">
            <title>Placebo to 100 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 100 μg once daily about an hour before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Percentage of Participants With Greater Than 33 Percent Reduction From Baseline in Mean Number of Nocturnal Voids to Days 29, 57, 113 and 169</title>
          <description>Part II outcomes tested the durability of the effect observed in Part I. Percentage of participants in each treatment arm that had a greater than 33% reduction from baseline to Days 29, 57, 113 and 169 in mean number of nocturnal voids. Nocturnal void data were recorded in participant diaries.</description>
          <population>Observed Cases (OC) Analysis Set which consisted of participants who had information on mean number of nocturnal voids for both the screening visit and the final visit in Part I (Day 28) and did not have any major protocol deviations. Participants had data representing the visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (n=104,100,93,104,22,28,27,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="73"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="48"/>
                    <measurement group_id="O8" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=86,85,78,81,17,24,21,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="71"/>
                    <measurement group_id="O7" value="43"/>
                    <measurement group_id="O8" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=53,56,49,47,11,15,13,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="87"/>
                    <measurement group_id="O5" value="55"/>
                    <measurement group_id="O6" value="73"/>
                    <measurement group_id="O7" value="54"/>
                    <measurement group_id="O8" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=17,15,17,15,3,3,4,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="87"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="67"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Change From Baseline in Total Reported Sleep Time at Week 4</title>
        <description>Total sleep time was recorded by participants in study diaries.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>Intent to treat (ITT) population --All randomized subjects who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., number of nocturnal voids) during Part I were included in the ITT analysis dataset. Participants analyzed had baseline and Week 4/Day 28/End of Part 1 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in Total Reported Sleep Time at Week 4</title>
          <description>Total sleep time was recorded by participants in study diaries.</description>
          <population>Intent to treat (ITT) population --All randomized subjects who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., number of nocturnal voids) during Part I were included in the ITT analysis dataset. Participants analyzed had baseline and Week 4/Day 28/End of Part 1 measurements.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="80.66"/>
                    <measurement group_id="O2" value="7.8" spread="58.55"/>
                    <measurement group_id="O3" value="15.9" spread="53.92"/>
                    <measurement group_id="O4" value="24.9" spread="72.21"/>
                    <measurement group_id="O5" value="19.0" spread="68.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Change From Baseline in Initial Period of Undisturbed Sleep at Week 4</title>
        <description>Initial period of undisturbed sleep was the time elapsed from first falling asleep until either first void or morning arising. Data were captured in patient diaries.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>ITT population --All randomized subjects who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., number of nocturnal voids) during Part I were included in the ITT analysis dataset. Participants with both baseline and Week 4/Day 28/End of Part I data are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in Initial Period of Undisturbed Sleep at Week 4</title>
          <description>Initial period of undisturbed sleep was the time elapsed from first falling asleep until either first void or morning arising. Data were captured in patient diaries.</description>
          <population>ITT population --All randomized subjects who received at least one dose of study drug and provided at least one primary efficacy measure (i.e., number of nocturnal voids) during Part I were included in the ITT analysis dataset. Participants with both baseline and Week 4/Day 28/End of Part I data are included.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="88.79"/>
                    <measurement group_id="O2" value="50.9" spread="111.47"/>
                    <measurement group_id="O3" value="82.7" spread="105.57"/>
                    <measurement group_id="O4" value="85.1" spread="109.33"/>
                    <measurement group_id="O5" value="106.7" spread="116.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Change From Baseline in Quality of Life Assessed by The International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) at Week 4</title>
        <description>The ICIQ-N is a self-administered questionnaire designed to assess the frequency and bother of daytime and nighttime urination. Subjects were asked to rate the degree of bother of daytime urination and nighttime urination on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate lower quality of life.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in Quality of Life Assessed by The International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) at Week 4</title>
          <description>The ICIQ-N is a self-administered questionnaire designed to assess the frequency and bother of daytime and nighttime urination. Subjects were asked to rate the degree of bother of daytime urination and nighttime urination on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate lower quality of life.</description>
          <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="137"/>
                <count group_id="O5" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daytime urination: How much does it bother you?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.61"/>
                    <measurement group_id="O2" value="-0.7" spread="2.59"/>
                    <measurement group_id="O3" value="-0.9" spread="2.96"/>
                    <measurement group_id="O4" value="-0.7" spread="2.86"/>
                    <measurement group_id="O5" value="-1.0" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime urination: How much does it bother you?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.86"/>
                    <measurement group_id="O2" value="-1.8" spread="2.96"/>
                    <measurement group_id="O3" value="-2.1" spread="3.19"/>
                    <measurement group_id="O4" value="-2.2" spread="3.33"/>
                    <measurement group_id="O5" value="-2.5" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Change From Baseline in the Two Domain Scores of the Nocturia Quality of Life (NQoL) Questionnaire at Week 4</title>
        <description>The NQoL questionnaire is a self-administered questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The twelve core questions are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. Domain summary scores were calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better quality of life.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in the Two Domain Scores of the Nocturia Quality of Life (NQoL) Questionnaire at Week 4</title>
          <description>The NQoL questionnaire is a self-administered questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The twelve core questions are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. Domain summary scores were calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better quality of life.</description>
          <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep/Energy Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="19.30"/>
                    <measurement group_id="O2" value="12.3" spread="23.54"/>
                    <measurement group_id="O3" value="14.6" spread="18.71"/>
                    <measurement group_id="O4" value="14.7" spread="20.92"/>
                    <measurement group_id="O5" value="16.3" spread="21.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother/Concern Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="19.73"/>
                    <measurement group_id="O2" value="14.7" spread="23.42"/>
                    <measurement group_id="O3" value="15.7" spread="21.29"/>
                    <measurement group_id="O4" value="15.2" spread="25.46"/>
                    <measurement group_id="O5" value="18.2" spread="23.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Change From Baseline in Quality of Sleep as Assessed by the Global Score of the Pittsburgh Sleep Quality Index (PSQI) at Week 4</title>
        <description>The PSQI is a self-administered 19-item questionnaire designed to assess sleep quality and disturbances. The global score ranges from 0 (better sleep quality) to 21 (worse sleep quality). Higher numbers indicate lower quality of life.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in Quality of Sleep as Assessed by the Global Score of the Pittsburgh Sleep Quality Index (PSQI) at Week 4</title>
          <description>The PSQI is a self-administered 19-item questionnaire designed to assess sleep quality and disturbances. The global score ranges from 0 (better sleep quality) to 21 (worse sleep quality). Higher numbers indicate lower quality of life.</description>
          <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="129"/>
                <count group_id="O5" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.8"/>
                    <measurement group_id="O2" value="-1.6" spread="2.8"/>
                    <measurement group_id="O3" value="-1.8" spread="3.0"/>
                    <measurement group_id="O4" value="-2.0" spread="3.2"/>
                    <measurement group_id="O5" value="-1.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Change From Baseline in the Mental Health Summary and the Physical Health Summary of the Short Form-12 Version 2 (SF-12v2) at Week 4</title>
        <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions. Data were analyzed using norm-based scoring and summarized along 2 dimensions: Physical Health Summary and Mental Health Summary. Each summary has a range from 0 (poor health) to 100 (highest level of health). Higher numbers indicate better quality of life.</description>
        <time_frame>- Week 3 to Day 1 (Baseline), Week 4 (end of Part I)</time_frame>
        <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in the Mental Health Summary and the Physical Health Summary of the Short Form-12 Version 2 (SF-12v2) at Week 4</title>
          <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions. Data were analyzed using norm-based scoring and summarized along 2 dimensions: Physical Health Summary and Mental Health Summary. Each summary has a range from 0 (poor health) to 100 (highest level of health). Higher numbers indicate better quality of life.</description>
          <population>Intent to treat population of participants who completed the questionnaire at both baseline and end of Part 1.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="137"/>
                <count group_id="O5" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Health Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="7.98"/>
                    <measurement group_id="O2" value="2.5" spread="8.06"/>
                    <measurement group_id="O3" value="2.1" spread="8.16"/>
                    <measurement group_id="O4" value="2.2" spread="8.39"/>
                    <measurement group_id="O5" value="1.7" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="6.81"/>
                    <measurement group_id="O2" value="0.5" spread="6.89"/>
                    <measurement group_id="O3" value="1.2" spread="7.17"/>
                    <measurement group_id="O4" value="0.6" spread="7.10"/>
                    <measurement group_id="O5" value="2.3" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Participants With Treatment-Emergent Adverse Events (AEs) During Study Part I</title>
        <description>A treatment-emergent adverse event (AE) was any AE occurring during the treatment period or a pretreatment AE that worsened in intensity during the treatment period. The treatment period was the period during which a subject received investigational medicinal product. If a subject discontinued the investigational medicinal product, the date of last dose was the last day of the treatment period.</description>
        <time_frame>Day 1 up to Week 4 (end of Part I)</time_frame>
        <population>Part I Safety Population includes study participants who received study intervention and had at least one safety assessment during study Part I.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'melt' for 28 days to complete Part I of the study. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt for between 1-6 months (until the database for part 1 was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Participants With Treatment-Emergent Adverse Events (AEs) During Study Part I</title>
          <description>A treatment-emergent adverse event (AE) was any AE occurring during the treatment period or a pretreatment AE that worsened in intensity during the treatment period. The treatment period was the period during which a subject received investigational medicinal product. If a subject discontinued the investigational medicinal product, the date of last dose was the last day of the treatment period.</description>
          <population>Part I Safety Population includes study participants who received study intervention and had at least one safety assessment during study Part I.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="103"/>
                    <measurement group_id="O5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse drug reactions (ADRs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="73"/>
                    <measurement group_id="O5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Participants With Treatment-Emergent Adverse Events (AEs) During Study Part II</title>
        <description>A treatment-emergent adverse event (AE) was any AE occurring during the treatment period or a pretreatment AE that worsened in intensity during the treatment period. The treatment period was the period during which a subject received investigational medicinal product. If a subject discontinued the investigational medicinal product, the date of last dose was the last day of the treatment period.</description>
        <time_frame>Week 5 up to Day 169</time_frame>
        <population>Part II Safety Population includes study participants who received study intervention and had at least one safety assessment during study Part II.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
          </group>
          <group group_id="O5">
            <title>Placebo to 10 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 10 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O6">
            <title>Placebo to 25 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 25 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O7">
            <title>Placebo to 50 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 50 μg once daily about an hour before bedtime.</description>
          </group>
          <group group_id="O8">
            <title>Placebo to 100 μg</title>
            <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 100 μg once daily about an hour before bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Participants With Treatment-Emergent Adverse Events (AEs) During Study Part II</title>
          <description>A treatment-emergent adverse event (AE) was any AE occurring during the treatment period or a pretreatment AE that worsened in intensity during the treatment period. The treatment period was the period during which a subject received investigational medicinal product. If a subject discontinued the investigational medicinal product, the date of last dose was the last day of the treatment period.</description>
          <population>Part II Safety Population includes study participants who received study intervention and had at least one safety assessment during study Part II.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="127"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Drug Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part I covers Day 1 to Week 4. Part II covers Week 5 up to Day169.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part I: Placebo</title>
          <description>Participants took a placebo ‘melt’ for 28 days to complete Part I of the study.</description>
        </group>
        <group group_id="E2">
          <title>Part I: Desmopressin Melt 10 μg</title>
          <description>Participants took desmopressin melt 10 μg for 28 days to complete Part I of the study.</description>
        </group>
        <group group_id="E3">
          <title>Part I: Desmopressin Melt 25 μg</title>
          <description>Participants took desmopressin melt 25 μg for 28 days to complete Part I of the study.</description>
        </group>
        <group group_id="E4">
          <title>Part I: Desmopressin Melt 50 μg</title>
          <description>Participants took desmopressin melt 50 μg for 28 days to complete Part I of the study.</description>
        </group>
        <group group_id="E5">
          <title>Part I: Desmopressin Melt 100 μg</title>
          <description>Participants took desmopressin melt 100 μg for 28 days to complete Part I of the study. Participants continued on this dose in study Part II for between 1-6 months (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="E6">
          <title>Part II: Desmopressin Melt 10 μg</title>
          <description>Participants who took desmopressin melt 10 μg in Part I of the study continued on this dose in Part II which ran between Months 1-6 (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="E7">
          <title>Part II: Desmopressin Melt 25 μg</title>
          <description>Participants who took desmopressin melt 25 μg in Part I of the study continued on this dose in Part II which ran between Months 1-6 (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="E8">
          <title>Part II: Desmopressin Melt 50 μg</title>
          <description>Participants who took desmopressin melt 50 μg in Part I of the study continued on this dose in Part II which ran between Months 1-6 (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="E9">
          <title>Part II: Desmopressin Melt 100 μg</title>
          <description>Participants who took desmopressin melt 100 μg in Part I of the study continued on this dose in Part II which ran between Months 1-6 (until the database for Part I was locked and treatment was unblinded).</description>
        </group>
        <group group_id="E10">
          <title>Part II: Placebo to Desmopressin Melt 10 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 10 μg once daily about an hour before bedtime</description>
        </group>
        <group group_id="E11">
          <title>Part II: Placebo to Desmopressin Melt 25 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 25 μg once daily about an hour before bedtime.</description>
        </group>
        <group group_id="E12">
          <title>Part II: Placebo to Desmopressin Melt 50 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 50 μg once daily about an hour before bedtime.</description>
        </group>
        <group group_id="E13">
          <title>Part II: Placebo to Desmopressin Melt 100 μg</title>
          <description>Participants randomized to Placebo in study Part I were re-randomized to receive active desmopressin in Part II. These participants were randomized to receive desmopressin melt 100 μg once daily about an hour before bedtime.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenosquamous cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="79" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="71" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="69" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="66" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="73" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="23" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="19" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="20" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="56" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="47" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="46" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="47" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

